Docetaxel‑Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15‑Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network

11/06/2024 17 min Episodio 57
Docetaxel‑Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15‑Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network

Listen "Docetaxel‑Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15‑Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network"

Episode Synopsis

Rick Greene, MD, discusses with Lorenzo Ferri, MD, PhD, the long-term survival outcomes of patients with esophageal and junctional adenocarcinoma treated with neoadjuvant docetaxel-based chemotherapy and en bloc transthoracic esophagectomy. Dr. Ferri is author of, "Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network." Dr. Ferri is Professor of Surgery and Oncology, McGill University; David S. Mulder Chair of Surgery Head, Division of Thoracic and Upper Gastrointestinal Surgery, McGill University Health Centre; and, Director, Upper G.I. Cancer Program, McGill University, Montreal, Canada.

More episodes of the podcast Speaking of SurgOnc